COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled …
ZR Yang, YW Jiang, FX Li, D Liu, TF Lin… - The Lancet …, 2023 - thelancet.com
Background The efficacy of SARS-CoV-2 vaccines in preventing severe COVID-19 illness
and death is uncertain due to the rarity of data in individual trials. How well the antibody …
and death is uncertain due to the rarity of data in individual trials. How well the antibody …
Advances in the design and development of SARS-CoV-2 vaccines
XL Peng, JSY Cheng, HL Gong, MD Yuan… - Military Medical …, 2021 - Springer
Since the end of 2019, coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The RNA …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The RNA …
Vaccines for COVID-19: a systematic review of immunogenicity, current development, and future prospects
Z Zhang, Q Shen, H Chang - Frontiers in immunology, 2022 - frontiersin.org
The persistent coronavirus disease 2019 (COVID-19), characterized by severe respiratory
syndrome, is caused by coronavirus 2 (SARS-CoV-2), and it poses a major threat to public …
syndrome, is caused by coronavirus 2 (SARS-CoV-2), and it poses a major threat to public …
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort …
N Wanlapakorn, N Suntronwong… - Human vaccines & …, 2022 - Taylor & Francis
In light of intermittent supply shortages of individual vaccines and evidence of rare but
serious adverse events after vaccination, heterologous regimens for COVID-19 vaccines …
serious adverse events after vaccination, heterologous regimens for COVID-19 vaccines …
CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
L Jin, Z Li, X Zhang, J Li, F Zhu - Human vaccines & …, 2022 - Taylor & Francis
CoronaVac, also known as the Sinovac inactivated SARS-CoV-2 vaccine, has been widely
implemented in combating the COVID-19 pandemic. We summarized the results of clinical …
implemented in combating the COVID-19 pandemic. We summarized the results of clinical …
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
LC Netto, KY Ibrahim, CM Picone, APPS Alves… - The Lancet …, 2022 - thelancet.com
Background People living with HIV might have a poor or delayed response to vaccines,
mainly when CD4 cell counts are low, and data concerning COVID-19 vaccines in this …
mainly when CD4 cell counts are low, and data concerning COVID-19 vaccines in this …
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK …
R Lazarus, B Querton, IC Ramljak… - The Lancet Infectious …, 2022 - thelancet.com
Summary Background The Valneva COVID-19 vaccine (VLA2001; Valneva Austria, Vienna,
Austria) is an inactivated whole-virus, adjuvanted SARS-CoV-2 vaccine. We aimed to …
Austria) is an inactivated whole-virus, adjuvanted SARS-CoV-2 vaccine. We aimed to …
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre …
JX Li, LH Hou, JB Gou, ZD Yin, SP Wu… - The Lancet Infectious …, 2023 - thelancet.com
Summary Background Aerosolised Ad5-nCoV is one of the first licensed mucosal respiratory
vaccine against SARS-CoV-2 in the world; however, the safety profile of this vaccine has not …
vaccine against SARS-CoV-2 in the world; however, the safety profile of this vaccine has not …
Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies
M Sadeghalvad, AH Mansourabadi… - Reviews in Medical …, 2023 - Wiley Online Library
Designing and manufacturing efficient vaccines against coronavirus disease 2019 (COVID‐
19) is a major objective. In this systematic review, we aimed to evaluate the most important …
19) is a major objective. In this systematic review, we aimed to evaluate the most important …